Back to top
more

Galapagos (GLPG)

(Delayed Data from NSDQ)

$29.58 USD

29.58
99,676

+0.24 (0.82%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead Inks Gene Editing Collaboration Deal for HBV Infection

by Zacks Equity Research

Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.

    Gilead's Rheumatoid Arthritis Drug Successful in Phase III

    by Zacks Equity Research

    Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.

      Vertex Completes Enrollment in Triple Combination Studies

      by Zacks Equity Research

      Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.

        Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

        by Zacks Equity Research

        Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

          Vertex Inks Reimbursement Agreement for Orkambi in Australia

          by Zacks Equity Research

          Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.

            Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2

            by Zacks Equity Research

            The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.

              Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected

              by Zacks Equity Research

              Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.

                Can the Rally in Galapagos (GLPG) Shares Continue?

                by Zacks Equity Research

                Galapagos NV (GLPG) has been on the move lately as the stock has risen by 23.4% in the past four weeks, and it is currently trading well above its 20-Day SMA

                  Galapagos (GLPG): Moving Average Crossover Alert

                  by Zacks Equity Research

                  Galapagos NV (GLPG) is looking like an interesting pick from a technical perspective

                    Vertex's Shares Rally as a Rival's CF Candidate Disappoints

                    by Zacks Equity Research

                    Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

                      Gilead & Galapagos Announce Positive Data on Filgotinib

                      by Zacks Equity Research

                      Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.

                        New Strong Sell Stocks for February 16th

                        by Zacks Equity Research

                        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                          Lilly's Taltz Positive in Phase III Label Expansion Study

                          by Zacks Equity Research

                          Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.

                            New Strong Sell Stocks for February 7th

                            by Zacks Equity Research

                            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

                              New Strong Sell Stocks for February 7th

                              by Zacks Equity Research

                              Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                Galapagos Reports Topline Data From Osteoarthritis Study

                                by Zacks Equity Research

                                Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.

                                  Galapagos' CF Candidate Shows Potential in Phase II Study

                                  by Zacks Equity Research

                                  Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.

                                    Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View

                                    by Zacks Equity Research

                                    Vertex Pharma (VRTX) third-quarter earnings increased from the year-ago period led by strong sales of CF drugs.

                                      Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?

                                      by Zacks Equity Research

                                      Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                        Quanta Services (PWR) Q2 Earnings: What's in the Cards?

                                        by Zacks Equity Research

                                        Quanta Services' (PWR) second-quarter 2017 earnings results will likely benefit from thriving engineering and project management services, but concerns like regulatory delays remain.

                                          GoPro (GPRO) to Report Q2 Earnings: A Beat in Store?

                                          by Zacks Equity Research

                                          GoPro's (GPRO) second-quarter 2017 results should benefit from strong market traction of HERO5 cameras and restructuring measures, but risks of declining revenues and stiff competition remain.

                                            Match Group (MTCH) to Report Q2 Earnings: What's in Store?

                                            by Zacks Equity Research

                                            Match Group's (MTCH) second-quarter 2017 earnings results should benefit from steady market traction and brand visibility, but concerns like currency volatility remain.

                                              Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales

                                              by Zacks Equity Research

                                              Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.

                                                Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?

                                                by Zacks Equity Research

                                                We expect second-quarter results of Flowserve (FLS) to gain traction from its strong operation model, solid productivity and geographical diversity.

                                                  Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session

                                                  by Zacks Equity Research

                                                  Galapagos (GLPG) was a big mover last session, as the company saw its shares rise over 6% on the day.